Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of 5-acetyl-2-thiopheneboronic acid cas 206551-43-1 in China. Welcome to wholesale bulk high quality 5-acetyl-2-thiopheneboronic acid cas 206551-43-1 for sale here from our factory. Good service and reasonable price are available.
5-Acetyl-2-thiopheneboronic acid, typically appears as a brown or creamy powder. The formation of this color is related to specific functional groups in its molecular structure, which exhibit specific colors under the action of light. The fineness of a powder is usually related to its preparation process and purity, and a high-quality substance should have a uniform and delicate powder like appearance. For example, it has a low solubility in water and usually needs to be dissolved well in organic solvents. This property is related to the hydrophobic groups in its molecular structure, making it difficult to form stable intermolecular interactions in water. Mainly used as synthetic raw materials in the pharmaceutical field. It can be used to synthesize various insecticides. These insecticides achieve the goal of killing pests by damaging their nervous system or interfering with their metabolic processes. At the same time, these insecticides have relatively low harm to the environment and human health, and have high safety.
|
|
|
|
Chemical Formula |
C6H7BO3S |
|
Exact Mass |
170 |
|
Molecular Weight |
170 |
|
m/z |
170 (100.0%), 169 (24.8%), 171 (6.5%), 172 (4.5%), 170 (1.6%), 171 (1.1%) |
|
Elemental Analysis |
C, 42.39; H, 4.15; B, 6.36; O, 28.24; S, 18.86 |
In the context of targeted therapy, 5-Acetyl-2-thiopheneboronic acid could potentially serve as a key intermediate or building block for the development of novel therapeutic agents. Targeted therapy aims to specifically inhibit the growth or progression of disease by targeting specific molecules or pathways that are involved in the disease process. This highly selective approach minimizes damage to healthy tissues and maximizes the effectiveness of treatment.
The role in targeted therapy may involve its use as a scaffold or starting point for the synthesis of more complex molecules that can bind to specific receptors or enzymes involved in diseases such as cancer, autoimmune disorders, or infectious diseases. By modifying its structure, researchers can potentially create new compounds that have enhanced affinity and selectivity for these targets.
Furthermore, the boron atom offers unique opportunities for the development of boron-based targeted therapies. Boron has been explored as a potential therapeutic agent due to its ability to form stable covalent bonds with certain biomolecules, such as proteins or nucleic acids. This property could be harnessed to create compounds that selectively target and inhibit the function of disease-related proteins.
What is Targeted therapy
Targeted therapy is a form of precision medicine that involves the use of drugs or other substances to specifically attack cancer cells or other disease-causing cells, while minimizing damage to healthy tissue. This approach differs from traditional therapies like chemotherapy and radiation, which often affect both healthy and diseased cells.
In targeted therapy, drugs are designed to interfere with specific molecules involved in the growth, progression, and spread of cancer or other diseases. These molecules, often called targets, may be proteins or other structures found on or within the cells. By targeting these specific molecules, the drugs can block the signals that tell the cells to grow and divide uncontrollably.
Targeted therapies can be classified into several types, including monoclonal antibodies, tyrosine kinase inhibitors, and other small molecules. Each type works in a different way to disrupt the signaling pathways that drive disease progression.
The development of targeted therapies has revolutionized the treatment of many types of cancer and other diseases, offering patients new options for more effective and less toxic treatments. As research continues, the field of targeted therapy is expected to expand, leading to even more advanced and personalized treatment options for patients.
|
|
|
Small Molecule Targeted Drugs: These drugs can penetrate cell membranes and bind to targets within cells, inhibiting the growth and reproduction of cancer cells. Common small molecule drugs include imatinib, erlotinib, gefitinib, etc., which are mainly used to treat certain types of leukemia, lung cancer, and other conditions.
Monoclonal Antibodies: Monoclonal antibodies are specific antibodies produced by a single B-cell clone that can bind to specific proteins on the surface of cancer cells, thereby playing a role in treating tumors. Common drugs include trastuzumab, pertuzumab, cetuximab, bevacizumab, etc. These drugs work by blocking signal transduction, marking cancer cells for immune system attack, or directly killing cancer cells.
Kinase Inhibitors: These drugs interfere with cancer cell signaling by inhibiting specific kinases, thereby inhibiting their growth and spread. Common kinase inhibitors include sorafenib, sunitinib, etc., which are mainly used to treat kidney cancer, liver cancer, and other conditions.
Immune Checkpoint Inhibitors: These drugs activate the body's immune response to cancer cells by blocking immune checkpoints such as PD-1 and PD-L1. Examples include pembrolizumab, nivolumab, atezolizumab, ipilimumab, etc. Immune checkpoint inhibitors have been widely used in the treatment of various cancers, such as melanoma and non-small cell lung cancer.
Antibody-Drug Conjugates (ADCs): ADCs are a type of compound preparation that links a monoclonal antibody to a cytotoxic drug. When the antibody binds to a specific antigen on the surface of a cancer cell, the cytotoxic drug is released to kill the cancer cell. Examples include enhertu (trastuzumab deruxtecan) and other similar drugs.
Fusion Proteins: Fusion proteins are substances formed by chemically combining two or more protein fragments. One fragment is a small molecule with biological activity, while the other is a large molecule carrier that stabilizes the protein structure. Common fusion proteins include bevacizumab, lapatinib, etc.
Antiangiogenic Drugs: These drugs promote the formation of new blood vessels to provide nutritional support, thereby prolonging the survival of patients. Common antiangiogenic drugs include bevacizumab, endostatin, etc.
commonly used drugs
Imatinib (Gleevec): This is a tyrosine kinase inhibitor primarily used to treat chronic myeloid leukemia and certain types of gastrointestinal stromal tumors. It works by blocking the enzyme that promotes cancer cell growth and survival.
Trastuzumab (Herceptin): A monoclonal antibody that targets HER2-positive breast cancer cells. By binding to HER2 receptors, trastuzumab blocks the growth signals that cancer cells need to proliferate.
Rituximab (Rituxan): This drug is a chimeric monoclonal antibody used in the treatment of non-Hodgkin's lymphoma and certain autoimmune diseases. It targets the CD20 antigen on B-cells, leading to cell death.
Osimertinib (Tagrisso): An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed for patients with EGFR mutation-positive non-small cell lung cancer. It effectively blocks the mutated EGFR, slowing tumor growth.
Vemurafenib (Zelboraf): Targeted against melanoma with a specific BRAF gene mutation, vemurafenib inhibits the mutated BRAF protein, thereby stopping or slowing cancer cell growth.
Crizotinib (Xalkori): Used in the treatment of non-small cell lung cancer with ALK gene rearrangements and certain types of ros1-positive lung cancer. It blocks the activity of ALK and ROS1 proteins.
Boric acid compounds play an indispensable role on the vast stage of contemporary organic chemistry, medicinal chemistry, and materials science. Among them, 5-Acetyl-2-thiopheneboronic Acid, as a structurally unique and functionally integrated molecule, is not an isolated "Eureka moment" in its discovery and development history, but a coevolutionary history driven by theoretical breakthroughs, methodological innovations, and application demands.
As early as 1860, Edward Frankland synthesized the first organic boron compound (diethylborane), but systematic research on organic boronic acids did not truly begin until the mid-20th century.
In 1956, Herbert C. Brown was awarded the 1979 Nobel Prize in Chemistry for his pioneering work in the borohydride reaction, which provided a powerful tool for the convenient synthesis of alkyl boron compounds from olefins and greatly promoted the development of organic boron chemistry. However, a universal synthesis method for more stable and valuable aromatic boronic acids has not yet been established.
Thiophene, as a five membered aromatic heterocyclic ring, can be traced back to 1883 when Victor Meyer accidentally discovered it in the chemical analysis of benzene. Thiophene rings have rich electronic properties, with slightly stronger aromaticity than benzene rings, and sulfur atoms provide potential coordination and chemical modification sites.
In the first half of the 20th century, thiophene chemistry mainly focused on the development of dyes, fragrances, and pharmaceutical intermediates. For example, the famous anti-inflammatory drug Tenoxicam and a range of antibacterial agents both contain thiophene skeletons. Acetyl (- COCH3), as an important functional group, is a representative of ketones and can be used for further derivatization (such as forming enolates, condensation reactions, reduction to alcohols, etc.). It is a common "handle" for constructing complex molecules.
Before the emergence of 5-acetyl-2-thiophene boronic acid, chemists were already able to synthesize 2-acetylthiophene and 2-thiophenboronic acid separately. However, the precise integration of these two highly valuable functional groups (acetyl and boronic acid) at specific positions (2nd and 5th positions) on the same thiophene ring requires more precise synthesis strategies and stronger application demands.
In the 1970s, palladium catalyzed cross coupling reactions began to emerge. In 1972, Ei ichi Negishi and Tsutomu Migita developed palladium catalyzed coupling of organotin compounds with acyl chlorides. In the same year, Richard F. Heck reported the palladium catalyzed coupling reaction (Heck reaction) of olefins with halogenated aromatic hydrocarbons. These findings provide powerful new tools for constructing carbon carbon bonds, but the organometallic reagents they use (such as organotin, organozinc, Grignard reagents) are often sensitive to air and water, and may be highly toxic.
In 1979, Professor Akira Suzuki and his colleague Norio Miyaura from Hokkaido University in Japan published a groundbreaking paper in Tetrahedral Communication. They found that under alkaline conditions and the presence of palladium catalyst, arylboronic acid can undergo coupling reaction with halogenated aromatic hydrocarbons to generate aromatic compounds. This is the Suzuki Miyaura coupling reaction later named after him.
Hot Tags: 5-acetyl-2-thiopheneboronic acid cas 206551-43-1, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 3-Phenyltoluene, Tetramethyl orthosilicate, Synthetic Chemical, 1 2 4 Triazole CAS 288 88 0, 2-Chloro-4-pyridinecarboxylic acid, 5 Acetyl 2 thiopheneboronic Acid CAS 206551 43 1